LUND, SWEDEN--(MARKET WIRE)--Jul 26, 2007 -- Active Biotech AB (OMX Nordic:ACTI) today announced that ANYARA has been granted Orphan Drug Status by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA). Orphan Drug designation provides a variety of incentives, including market exclusivity for up to 10 years following approval.
